JP2001511149A5 - - Google Patents

Download PDF

Info

Publication number
JP2001511149A5
JP2001511149A5 JP1998533114A JP53311498A JP2001511149A5 JP 2001511149 A5 JP2001511149 A5 JP 2001511149A5 JP 1998533114 A JP1998533114 A JP 1998533114A JP 53311498 A JP53311498 A JP 53311498A JP 2001511149 A5 JP2001511149 A5 JP 2001511149A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998533114A
Other languages
English (en)
Other versions
JP2001511149A (ja
Filing date
Publication date
Priority claimed from US08/791,391 external-priority patent/US6590079B2/en
Application filed filed Critical
Publication of JP2001511149A publication Critical patent/JP2001511149A/ja
Publication of JP2001511149A5 publication Critical patent/JP2001511149A5/ja
Ceased legal-status Critical Current

Links

Description

Figure 2001511149
Figure 2001511149
Figure 2001511149
Figure 2001511149
JP53311498A 1997-01-30 1998-01-30 抗αｖβ３組換えヒト化抗体、これをコードする核酸、および使用の方法 Ceased JP2001511149A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/791,391 1997-01-30
US08/791,391 US6590079B2 (en) 1997-01-30 1997-01-30 Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
PCT/US1998/001826 WO1998033919A2 (en) 1997-01-30 1998-01-30 Anti-alpha-v beta-3 recombinant humanized antibodies, nucleic acids encoding same and methods of use

Publications (2)

Publication Number Publication Date
JP2001511149A JP2001511149A (ja) 2001-08-07
JP2001511149A5 true JP2001511149A5 (ja) 2005-10-06

Family

ID=25153592

Family Applications (1)

Application Number Title Priority Date Filing Date
JP53311498A Ceased JP2001511149A (ja) 1997-01-30 1998-01-30 抗αｖβ３組換えヒト化抗体、これをコードする核酸、および使用の方法

Country Status (6)

Country Link
US (2) US6590079B2 (ja)
EP (1) EP0970217A2 (ja)
JP (1) JP2001511149A (ja)
AU (1) AU737569B2 (ja)
CA (1) CA2278848A1 (ja)
WO (1) WO1998033919A2 (ja)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6590079B2 (en) * 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6596850B1 (en) * 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
US20010011125A1 (en) * 1997-01-30 2001-08-02 William D. Huse Anti-alpha v beta 3 recombinant human antibodies, nucleic acids encoding same and methods of use
CA2351452A1 (en) * 1998-12-04 2000-06-15 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor .alpha.v.beta.3
US6521593B1 (en) * 1999-02-01 2003-02-18 Childrens Hospital Los Angeles Methods for inhibiting brain tumor growth
US6531580B1 (en) * 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
EP1239877B1 (en) * 1999-10-06 2008-01-09 Abbott GmbH & Co. KG Composition comprising a tnf-alpha inhibitor and an integrin alphavbeta3 receptor antagonist
US7229619B1 (en) 2000-11-28 2007-06-12 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
US20010034062A1 (en) * 2000-02-09 2001-10-25 Scott Koenig Antibody gene therapy with adeno-associated viral vectors
US7179900B2 (en) 2000-11-28 2007-02-20 Medimmune, Inc. Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
CA2439852A1 (en) * 2001-03-02 2002-09-12 Christine Dingivan Methods of preventing or treating inflammatory or autoimmune disorders by administering integrin alphav beta3 antagonists
AU2002316855B2 (en) * 2001-04-24 2008-03-13 Merck Patent Gmbh Combination therapy using anti-angiogenic agents and TNFalpha
IL161162A0 (en) * 2001-10-10 2004-08-31 Pharmacia Italia Spa Methods for preventing and treating bone loss with steroid compounds
US7365167B2 (en) 2001-11-26 2008-04-29 Cell Matrix, Inc. Humanized collagen antibodies and related methods
US7390885B2 (en) 2001-11-26 2008-06-24 Cell Matrix, Inc. Humanized collagen antibodies and related methods
WO2003075741A2 (en) * 2002-03-04 2003-09-18 Medimmune, Inc. METHODS OF PREVENTING OR TREATING DISORDERS BY ADMINISTERING AN INTEGRIN αvβ3 ANTAGONIST IN COMBINATION WITH AN HMG-CoA REDUCTASE INHIBITOR OR A BISPHOSPHONATE
US20040001835A1 (en) * 2002-03-04 2004-01-01 Medimmune, Inc. Prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents
EP1513879B1 (en) * 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
US20040176272A1 (en) * 2003-01-30 2004-09-09 Medimmune, Inc. Uses of integrin alphavbeta3 antagonists
EP1589996A4 (en) * 2003-01-30 2009-01-21 Medimmune Inc ANTI-INTEGRIN ALPHA BETA 3 ANTIBODY FORMULATIONS AND ITS USES
US20040208869A1 (en) * 2003-01-30 2004-10-21 Medimmune, Inc. Uses of anti-integrin alphanubeta3 antibody formulations
GB0302699D0 (en) * 2003-02-06 2003-03-12 Univ Bradford Immunoglobulin
WO2004091510A2 (en) 2003-04-11 2004-10-28 Medimmune, Inc. Recombinant il-9 antibodies and uses thereof
US7351739B2 (en) 2004-04-30 2008-04-01 Wellgen, Inc. Bioactive compounds and methods of uses thereof
US8187595B2 (en) 2004-05-07 2012-05-29 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor-I
WO2005117936A2 (en) 2004-05-07 2005-12-15 The University Of North Carolina At Chapel Hill Method for enhancing or inhibiting insulin-like growth factor-i
US7659374B2 (en) * 2004-08-16 2010-02-09 Medimmune, Llc Eph receptor Fc variants with enhanced antibody dependent cell-mediated cytotoxicity activity
EP2422811A2 (en) 2004-10-27 2012-02-29 MedImmune, LLC Modulation of antibody specificity by tailoring the affinity to cognate antigens
AU2005313026B2 (en) 2004-12-06 2011-09-08 Kyowa Hakko Kirin Co., Ltd. Human monoclonal antibodies to influenza M2 protein and methods of making and using same
US8901281B2 (en) 2005-06-17 2014-12-02 Merck Sharp & Dohme Corp. ILT3 binding molecules and uses therefor
US20070110757A1 (en) 2005-06-23 2007-05-17 Ziping Wei Antibody formulations having optimized aggregation and fragmentation profiles
JP5597793B2 (ja) 2006-06-19 2014-10-01 メルク・シャープ・アンド・ドーム・コーポレーション Ｉｌｔ３結合分子およびその使用
EP2043603A4 (en) 2006-07-11 2010-10-27 Arubor Corp PREVENTION AND THERAPY OF RHINOSINUSITIS WITH PROINFLAMMATORY CYTOKINHERMERS
AU2007284690A1 (en) 2006-08-10 2008-02-21 Roy C. Levitt Localized therapy of lower airways inflammatory disorders with proinflammatory cytokine inhibitors
WO2008048545A2 (en) 2006-10-16 2008-04-24 Medimmune, Llc. Molecules with reduced half-lives, compositions and uses thereof
CN101820898B (zh) * 2007-05-16 2013-10-30 中国抗体制药有限公司 互补决定区（CDRs）功能人源化
EP1997830A1 (en) 2007-06-01 2008-12-03 AIMM Therapeutics B.V. RSV specific binding molecules and means for producing them
US8633139B2 (en) 2007-12-21 2014-01-21 Abbvie Biotherapeutics Inc. Methods of screening complex protein libraries to identify altered properties
EP2303924B1 (en) 2008-06-16 2016-07-27 Patrys Limited Lm-antibodies, functional fragments, lm-1 target antigen, and methods for making and using same
WO2010141329A1 (en) 2009-06-01 2010-12-09 Medimmune, Llc Molecules with extended half-lives and uses thereof
US8568726B2 (en) 2009-10-06 2013-10-29 Medimmune Limited RSV specific binding molecule
PL2797951T3 (pl) 2011-12-28 2018-07-31 Immunoqure Ag Sposób izolacji ludzkich przeciwciał
WO2014036385A1 (en) 2012-08-31 2014-03-06 The University Of North Carolina At Chapel Hill Monoclonal antibodies for enhancing or inhibiting insulin-like growth factor 1 (igf-1)
US10112995B2 (en) 2013-07-03 2018-10-30 Immunoqure Ag Human anti-IFN-α antibodies
KR102630070B1 (ko) 2017-03-31 2024-01-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 알파-v 베타-3-양성인 암 줄기 세포(csc)를 표적화하여 사멸시키고 약물 내성 암을 치료하기 위한 조성물 및 방법
KR102098462B1 (ko) * 2018-03-14 2020-04-08 가톨릭대학교 산학협력단 αvβ3 인테그린 표적 단일 도메인 항체

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5264563A (en) 1990-08-24 1993-11-23 Ixsys Inc. Process for synthesizing oligonucleotides with random codons
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
JP3353209B2 (ja) * 1992-04-03 2002-12-03 ジェネンテク，インコーポレイテッド αｖβ３インテグリンに対する抗体
IT1268004B1 (it) * 1994-02-02 1997-02-20 Giuseppe Lambertini Dispositivo per il bloccaggio di un pezzo su un piano d'appoggio, quale una tavola di macchina operatrice.
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP0835135A2 (en) 1995-06-07 1998-04-15 Centocor, Inc. Platelet-specific chimeric immunoglobulin and methods of use therefor
US6590079B2 (en) 1997-01-30 2003-07-08 Ixsys, Incorporated Anti-αvβ3 recombinant human antibodies, nucleic acids encoding same
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same

Similar Documents

Publication Publication Date Title
JP2000510751A5 (ja)
JP2000509912A5 (ja)
JP2000509637A5 (ja)
JP2000509942A5 (ja)
JP2000509635A5 (ja)
JP2001527609A5 (ja)
JP2002514069A5 (ja)
JP2001500351A5 (ja)
JP2000509587A5 (ja)
JP2001519086A5 (ja)
JP2000510793A5 (ja)
JP2000508866A5 (ja)
JP2001511149A5 (ja)
JP2002508864A5 (ja)
JP2000508841A5 (ja)
JP2001509197A5 (ja)
JP2000508680A5 (ja)
JP2002510288A5 (ja)
JP2000509804A5 (ja)
JP2000509853A5 (ja)
JP2000509755A5 (ja)
JP2000510969A5 (ja)
JP2000508836A5 (ja)
JP2000510247A5 (ja)
JP2000509520A5 (ja)